PT Telekomunikasi Indonesia Tbk Holds Extraordinary General Meeting
PT Telekomunikasi Indonesia Tbk reports on its Extraordinary General Meeting, highlighting key decisions and future directions for the company.
Ruanyun Edai Technology forecasts strong revenue growth
Ruanyun Edai Technology Inc. anticipates first-half fiscal 2027 revenue to surpass full-year revenue from the last two years, driven by Smart Campus Services.
KE Holdings grants 471,120 RSUs to employees to boost retention
KE Holdings Inc. announces the grant of 471,120 RSUs to employees, aiming to align interests and boost retention under its 2020 Share Incentive Plan.
Evaxion to Present New Data for Cancer Vaccine EVX-01 at SITC
Evaxion A/S announces presentation of new immune data for its cancer vaccine EVX-01 at SITC 2026 Annual Meeting, showcasing advancements in AI-driven immunotherapy.
Phaos Technology Holdings Announces 1-for-15 Reverse Stock Split
Phaos Technology Holdings will execute a 1-for-15 reverse stock split effective October 12, 2026, aimed at enhancing its market presence.
GSK Reports Phase III Trial Success for Osteosarcoma Drug
GSK plc announces positive phase III trial results for Ris-Rez in treating relapsed osteosarcoma, showing a 67% reduction in disease progression.
Kanzhun Ltd announces resignation of non-executive director
Kanzhun Ltd announces Haiyang Yu's resignation as non-executive director, effective October 23, 2026, signaling leadership changes in the online recruitment sector.
Brainsway Expands U.S. Insurance Coverage for Deep TMS Treatment
Brainsway Ltd. expands U.S. insurance coverage for Deep TMS treatment of OCD, now reaching over 118 million lives, enhancing patient access to innovative therapies.
Can-Fite BioPharma Reports Positive Phase IIa Study Results
Can-Fite BioPharma presents positive Phase IIa data for namodenoson in pancreatic cancer at ESMO 2026, marking a significant step for the company.
GSK Reports Positive Phase I Data for Ovarian Cancer Drug
GSK plc presents encouraging results for Mo-Rez, a new treatment for platinum-resistant ovarian cancer, showing a 62% response rate in phase I trials.
GSK Reports 76% Response Rate for Jemperli in Cancer Trial
GSK plc announces a 76% complete response rate for Jemperli in a rectal cancer trial, marking a potential shift in treatment approaches.
Turkcell announces major share buy-back program
Turkcell Iletisim Hizmetleri A.S. initiates a buy-back of over 3 million shares to strengthen shareholder value and market position.
Dr. Reddy's Laboratories appoints Akhil Ravi as Head API
Dr. Reddy's Laboratories announces the appointment of Akhil Ravi as Head API and Services, effective November 13, 2026, enhancing its leadership team.
BioNTech, DualityBio report Phase 3 trial results for breast cancer
BioNTech SE and DualityBiologics announce topline results from the DYNASTY-Breast02 Phase 3 trial, showing modest benefits for breast cancer treatment.
Sanofi breaks ground on new insulin manufacturing facility
Sanofi has begun construction on a new insulin manufacturing facility in Frankfurt, Germany, to enhance production capacity for diabetes treatments.
111, Inc. Appoints Advisors to Review Strategic Proposal
111, Inc. engages independent advisors to evaluate a strategic proposal, marking a pivotal moment in its transformation within the retail-drug sector.
ICICI Bank receives credit rating reaffirmation from ICRA, CARE
ICICI Bank's credit ratings reaffirmed by ICRA and CARE Ratings, indicating stability in the commercial banking sector and boosting investor confidence.
Nanobiotix Reports Positive Phase 1 Data for Melanoma Therapy
Nanobiotix S.A. announces promising Phase 1 study results for JNJ-1900 (NBTXR3) in anti-PD-1-resistant melanoma, showing a 41.7% response rate.
NetClass Technology to Hold Extraordinary Shareholder Meeting
NetClass Technology Inc. announces an extraordinary general meeting on share consolidation, set for November 10, 2026, in Singapore.
AI OKTO Corp. declares $3.50 special dividend for shareholders
AI OKTO Corp. announces a special dividend of $3.50 per share, payable on November 25, 2026, reflecting strong financial performance.